Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma
Authors:
Abstract
Although antiandrogen withdrawal has moderate efficacy in patients with hormone refractory prostate carcinoma (HRPC), the effect of the simultaneous suppression of adrenal androgens with ketoconazole at the time of antiandrogen withdrawal is not known. Twenty consecutive patients with HRPC who had developed progressive disease despite combined androgen blockade were treated with antiandrogen withdrawal and simultaneous ketoconazole as a means of inhibiting adrenal steroid production. Prostate specific antigen (PSA) response was defined as a > 50% fall in PSA from baseline that was maintained for at least 8 weeks. Ten patients had established metastatic disease, 2 had high PSAs and no imaging studies (PSA of 70 and 160 ng/mL, respectively), 3 had microscopically positive lymph nodes and serologic progression, and 5 had serologic progression alone. Overall, of 20 evaluable patients, 11 (55%) had a > 50% fall in PSA (95% confidence interval [CI], 31.5-76.9%). The median PSA response duration was 8.5 months (95% CI, 7-17 months). The median survival was 19 months. Toxicity was mild, with Grade 1 and 2 nausea and emesis in 15% of patients, Grade 1 fatigue in 10% of patients, and reversible Grade 1 or 2 hepatotoxicity in 10% of patients. Mild skin toxicity was observed in 20% of patients. The addition of ketoconazole and hydrocortisone to antiandrogen withdrawal appears to increase the PSA response proportion observed with antiandrogen withdrawal alone. Toxicity is mild. Cancer 1997; 80:1755-9. © 1997 American Cancer Society.Keywords
This publication has 12 references indexed in Scilit:
- Ketoconazole Retains Activity in Advanced Prostate Cancer Patients with Progression Despite Flutamide WithdrawalJournal of Urology, 1997
- Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.Journal of Clinical Oncology, 1997
- The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancerCancer, 1995
- Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.Journal of Clinical Oncology, 1995
- Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate CancerNew England Journal of Medicine, 1995
- Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndromeUrology, 1994
- Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of "Hormone-Refractory" Prostate CancerJNCI: Journal of the National Cancer Institute, 1994
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- High-Dose Ketoconazole Therapy in Patients with Metastatic Prostate CancerAmerican Journal of Clinical Oncology, 1986
- KETOCONAZOLE THERAPY FOR ADVANCED PROSTATE CANCERThe Lancet, 1984